These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7473144)

  • 1. Pharmacological characterization of GT-2016, a non-thiourea-containing histamine H3 receptor antagonist: in vitro and in vivo studies.
    Tedford CE; Yates SL; Pawlowski GP; Nalwalk JW; Hough LB; Khan MA; Phillips JG; Durant GJ; Frederickson RC
    J Pharmacol Exp Ther; 1995 Nov; 275(2):598-604. PubMed ID: 7473144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
    Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
    J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands.
    Tedford CE; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Handley MK; Yates SL
    J Pharmacol Exp Ther; 1999 May; 289(2):1160-8. PubMed ID: 10215700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations.
    Krueger KM; Witte DG; Ireland-Denny L; Miller TR; Baranowski JL; Buckner S; Milicic I; Esbenshade TA; Hancock AA
    J Pharmacol Exp Ther; 2005 Jul; 314(1):271-81. PubMed ID: 15821027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor.
    Ito S; Yoshimoto R; Miyamoto Y; Mitobe Y; Nakamura T; Ishihara A; MacNeil DJ; Kanatani A; Tokita S
    Eur J Pharmacol; 2006 Jan; 529(1-3):40-6. PubMed ID: 16316645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist.
    Ligneau X; Lin J; Vanni-Mercier G; Jouvet M; Muir JL; Ganellin CR; Stark H; Elz S; Schunack W; Schwartz J
    J Pharmacol Exp Ther; 1998 Nov; 287(2):658-66. PubMed ID: 9808693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-[2-(4-imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist.
    Garbarg M; Arrang JM; Rouleau A; Ligneau X; Tuong MD; Schwartz JC; Ganellin CR
    J Pharmacol Exp Ther; 1992 Oct; 263(1):304-10. PubMed ID: 1383495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Search for novel leads for histamine H3-receptor antagonists: oxygen-containing derivatives.
    Stark H; Hüls A; Ligneau X; Arrang JM; Schwartz JC; Schunack W
    Pharmazie; 1997 Jul; 52(7):495-500. PubMed ID: 9266588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand.
    Witte DG; Yao BB; Miller TR; Carr TL; Cassar S; Sharma R; Faghih R; Surber BW; Esbenshade TA; Hancock AA; Krueger KM
    Br J Pharmacol; 2006 Jul; 148(5):657-70. PubMed ID: 16715122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [125I]iodoproxyfan and related compounds: a reversible radioligand and novel classes of antagonists with high affinity and selectivity for the histamine H3 receptor.
    Stark H; Purand K; Hüls A; Ligneau X; Garbarg M; Schwartz JC; Schunack W
    J Med Chem; 1996 Mar; 39(6):1220-6. PubMed ID: 8632428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
    McLeod RL; Rizzo CA; West RE; Aslanian R; McCormick K; Bryant M; Hsieh Y; Korfmacher W; Mingo GG; Varty L; Williams SM; Shih NY; Egan RW; Hey JA
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1037-44. PubMed ID: 12649305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons.
    Dai H; Fu Q; Shen Y; Hu W; Zhang Z; Timmerman H; Leurs R; Chen Z
    Eur J Pharmacol; 2007 Jun; 563(1-3):117-23. PubMed ID: 17350613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel series of (phenoxyalkyl)imidazoles as potent H3-receptor histamine antagonists.
    Ganellin CR; Fkyerat A; Bang-Andersen B; Athmani S; Tertiuk W; Garbarg M; Ligneau X; Schwartz JC
    J Med Chem; 1996 Sep; 39(19):3806-13. PubMed ID: 8809168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
    Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
    Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H3-receptor antagonists: synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles.
    Mor M; Bordi F; Silva C; Rivara S; Crivori P; Plazzi PV; Ballabeni V; Caretta A; Barocelli E; Impicciatore M; Carrupt PA; Testa B
    J Med Chem; 1997 Aug; 40(16):2571-8. PubMed ID: 9258364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds.
    Mikó T; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2003 Apr; 46(8):1523-30. PubMed ID: 12672253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971.
    Hey JA; Aslanian R; Bolser DC; Chapman RW; Egan RW; Rizzo CA; Shih NY; Fernandez X; McLeod RL; West R; Kreutner W
    Arzneimittelforschung; 1998 Sep; 48(9):881-8. PubMed ID: 9793613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
    Esbenshade TA; Fox GB; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan L; Wetter J; Marsh K; Bennani YL; Cowart MD; Sullivan JP; Hancock AA
    J Pharmacol Exp Ther; 2005 Apr; 313(1):165-75. PubMed ID: 15608078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substituted N-phenylcarbamates as histamine H3 receptor antagonists with improved in vivo potency.
    Reidemeister S; Stark H; Ligneau X; Ganellin CR; Schwartz JC; Schunack W
    Pharmazie; 2000 Feb; 55(2):83-6. PubMed ID: 10723763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-Alkynylphenyl imidazolylpropyl ethers as selective histamine H3-receptor antagonists with high oral central nervous system activity.
    Krause M; Ligneau X; Stark H; Garbarg M; Schwartz JC; Schunack W
    J Med Chem; 1998 Oct; 41(21):4171-6. PubMed ID: 9767653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.